NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
NeuroSense Therapeutics Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$2.67−0.40 (-13.19%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$21.14 (−88.80%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$11.13M
- EPS, diluted
- -$8.80
- Free cash flow
- -$7.68M
Eight years at a glance
Fiscal years 2018 to 2025, USD
Operating income
-$11.09M
Net income
-$11.13M
EPS, diluted
-$8.80
Free cash flow
-$7.68M
Reported period